93 [89Zr]Zr-DFO-durvalumab PET/CT before durvalumab treatment in R/M SCCHN patients To correct for partial volume effect, the correlation of [89Zr]Zr-DFO-durvalumab SUVpeak and TTB ratio with PFS was also performed after correcting for lesions <20mm, showing no essential differences between results described for all lesions (Supplementary Figure S6). A B Figure 5. Kaplan-Meier estimates of progression free survival based on [89Zr]Zr-DFO-durvalumab SUVpeak (A) and tumorto-blood-ratios (B) dichotomized at median value In total, 35 lesions were visible on evaluation CT scans during treatment. On a lesion level, [89Zr]Zr-DFO-durvalumab accumulation and treatment response was variable (Figure 6). There was no substantial correlation between lesional [89Zr]Zr-DFO-durvalumab SUVpeak or TTB ratio with the change in lesion size at 12 weeks (Spearman ρ 0.45, p= 0.051 and Spearman ρ -0.669, p= 0.78, respectively). A cut-off of the median SUVpeak of these lesions did not improve 5
RkJQdWJsaXNoZXIy MTk4NDMw